drugset / Trial / NCT03400865
Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas
Unknown
30 enrolled
Zhebao Wu
Beijing Tiantan Hospital · collabChinese PLA General Hospital · collabFirst Affiliated Hospital of Fujian Medical University · collabFirst Affiliated Hospital of Wenzhou Medical University · collabFirst Hospital of China Medical University · collabHuashan Hospital · collabPeking Union Medical College Hospital · collabXinqiao Hospital of Chongqing · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to preliminarily evaluate the safety and efficacy of cabergoline combined hydroxychloroquine/chloroquine(HCQ/CQ) therapy for cabergoline-Resistant Prolactinomas
Timeline
- Start
- 2018-10-25
- Primary completion
- 2020-12-30
- Completion
- 2020-12-30
Publications
- Background Leng ZG, Lin SJ, Wu ZR, Guo YH, Cai L, Shang HB, Tang H, Xue YJ, Lou MQ, Zhao W, Le WD, Zhao WG, Zhang X, Wu ZB. Activation of DRD5 (dopamine receptor D5) inhibits tumor growth by autophagic cell death. Autophagy. 2017 Aug 3;13(8):1404-1419. doi: 10.1080/15548627.2017.1328347. Epub 2017 Jun 14.
- Background Lin SJ, Leng ZG, Guo YH, Cai L, Cai Y, Li N, Shang HB, Le WD, Zhao WG, Wu ZB. Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline. Oncotarget. 2015 Nov 17;6(36):39329-41. doi: 10.18632/oncotarget.5744.
- Results Lin SJ, Wu ZR, Cao L, Zhang Y, Leng ZG, Guo YH, Shang HB, Zhao WG, Zhang X, Wu ZB. Pituitary Tumor Suppression by Combination of Cabergoline and Chloroquine. J Clin Endocrinol Metab. 2017 Oct 1;102(10):3692-3703. doi: 10.1210/jc.2017-00627.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabergoline | Small molecule | 2 mg | — |
| Subject | Chloroquine | Small molecule | — | — |
| Subject | Hydroxychloroquine | Small molecule | 5 mg/kg | — |